Evaluación in vitro de los ácidos octanoico y decanoico como tratamiento para el cáncer de glioblastoma
Glioblastoma is the most aggressive and malignant tumor of the brain, with a survival rate of no more than 12 months. Currently, resistance to treatments has been evidenced, so there is a need to explore adjuvant therapies to those that already exist. Among them is the ketogenic diet based on medium...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | |
| Formato: | Trabajo de grado (Pregrado y/o Especialización) |
| Lenguaje: | spa |
| Publicado: |
Universidad Antonio Nariño
2023
|
| Materias: | |
| Acceso en línea: | http://repositorio.uan.edu.co/handle/123456789/7386 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Glioblastoma is the most aggressive and malignant tumor of the brain, with a survival rate of no more
than 12 months. Currently, resistance to treatments has been evidenced, so there is a need to explore
adjuvant therapies to those that already exist. Among them is the ketogenic diet based on medium-chain
free fatty acids, which has shown antiangiogenic, anti-inflammatory and proapoptotic properties in
various diseases. In this study, cell overload, oxidative stress, and the relative expression of PTEN,
CCND3, HIF 1α, and BCL2 tumor genes in T98G cells after octanoic and decanoic acid
supplementation for 3 days were evaluated. A reduction in cell turnover, superoxide levels and reactive oxygen species was found in both octanoic acid and decanoic acid treated cells. In addition, a reduction
of BCL2 in cells with decanoic acid and an increase in the expression of PTEN with low glucose
octanoic acid is evidenced, which suggests a recovery in the control of cell death. The study
demonstrates the potential in vitro use of medium chain fatty acids as adjuvant therapy |
|---|
